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Abstract
Background
Acute Exacerbations of COPD (AECOPD) identified from electronic healthcare records
(EHR) are important for research, public health and to inform healthcare utilisation and ser-
vice provision. However, there is no standardised method of identifying AECOPD in UK
EHR. We aimed to validate the recording of AECOPD in UK EHR.
Methods
We randomly selected 1385 patients with COPD from the Clinical Practice Research Data-
link. We selected dates of possible AECOPD based on 15 different algorithms between Jan-
uary 2004 and August 2013. Questionnaires were sent to GPs asking for confirmation of
their patients’ AECOPD on the dates identified and for any additional relevant information.
Responses were reviewed independently by two respiratory physicians. Positive predictive
value (PPV) and sensitivity were calculated.
Results
The response rate was 71.3%. AECOPD diagnostic codes, lower respiratory tract infection
(LRTI) codes, and prescriptions of antibiotics and oral corticosteroids (OCS) together for
5–14 days had a high PPV (>75%) for identifying AECOPD. Symptom-based algorithms
and prescription of antibiotics or OCS alone had lower PPVs (60–75%). A combined strat-
egy of antibiotic and OCS prescriptions for 5–14 days, or LRTI or AECOPD code resulted in
a PPV of 85.5% (95% CI, 82.7–88.3%) and a sensitivity of 62.9% (55.4–70.4%).
Conclusion
Using a combination of diagnostic and therapy codes, the validity of AECOPD identified
from EHR can be high. These strategies are useful for understanding health-care utilisation
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for AECOPD, informing service provision and for researchers. These results highlight the
need for common coding strategies to be adopted in primary care to allow easy and accu-
rate identification of events.
Introduction
Chronic obstructive pulmonary disease (COPD) is a common, progressive disease character-
ised by airflow obstruction which is not fully reversible. As the third leading cause of death
worldwide[1], COPD represents a substantial public health problem. Acute exacerbations of
COPD (AECOPD) are important drivers of mortality[2, 3] and reduced quality of life[4] in
COPD patients and as the second most common reason for emergency hospital admission[5],
they are also of great public health importance. Several studies[6–8] of AECOPD have been
conducted in UK electronic healthcare records (EHR) which are becoming an increasingly
important resource for evidence from real life research.
Data from primary care are used by organisations such as Public Health England (PHE)
to compare data on AECOPD incidence and management across localities and by clinical
commissioning groups to inform delivery of care and design of services. In addition, the
recording of AECOPDs is important for clinicians as GPs need an easy and reliable way of
accessing information on the timing and severity of previous AECOPD to tailor management
programmes for their patients.
The investigation of AECOPD using EHR has so far been limited by the use of non-vali-
dated strategies to identify AECOPD events based on clinical experience. Previous studies used
different combinations of drug therapy (for example, oral steroids and/or antibiotics)[7] and/
or medical diagnosis codes. However, the validity of these approaches is not clear. Antibiotics
may not be given if AECOPD are thought to be viral and, therefore, use of prescription of anti-
biotics alone may lead to misclassification of other diseases for AECOPD, particularly as up to
50% of AECOPD are known to be associated with a virus[9]. In addition, these prescriptions
may be rescue packs intended for future use and may not represent individual acute events.
This study aimed to investigate a comprehensive set of pre-specified algorithms for the
identification of AECOPD within UK primary care electronic healthcare records.
Methods
Data source
We used the Clinical Practice Research Datalink (CPRD), a large electronic database of UK
general practice data that has been widely used for research. The Clinical Research Practice
Datalink (CPRD)[10] is a large electronic database of primary care medical records. CPRD
contains anonymised records for over 13 million patients, of which 4.4 million are currently
registered with a practice that is contributing data to the CPRD, representing about 7% of the
UK population. Data held include information on consultations, diagnoses, tests, referrals to
secondary care and prescriptions from primary care as well as some lifestyle data. Around 60%
of the patients included in the CPRD have been linked to hospital episode statistics data (HES).
Codelist and algorithm development
Codelists (Read codes and product codes) were developed prior to the beginning of the study.
Read codes are a hierarchical coding system of clinical terms used in the UK general practice
Validation of the Recording of AECOPD
PLOSONE | DOI:10.1371/journal.pone.0151357 March 9, 2016 2 / 14
Funding: This study was partly supported by a
GlaxoSmithKline and Medical Research Council
(MRC) industry partnership award. Hana Müllerová
and Kourtney Davis are employed by GSK and hold
stock and share options of GlaxoSmithKline Plc. JKQ
reports grants from MRC and grants from GSK during
the conduct of the study; grants from MRC, grants
from BLF, personal fees from AZ, personal fees from
GSK, and grants from Wellcome Trust outside the
submitted work. JRH reports personal fees from
Pharmaceutical companies interested in COPD,
including AZ, Chiesi, GSK, Novartis, Pfizer, and
Takeda, outside the submitted work. Imperial College
of Science, Technology and Medicine. LS reports
grants from Wellcome Trust, during the conduct of the
study; grants from Wellcome Trust, grants from MRC,
grants from NIHR, and personal fees from GSK,
outside the submitted work. There are no patents,
products in development or marketed products to
declare. This does not alter the authors’ adherence to
all the PLOS ONE policies on sharing data and
materials, as detailed online in the guide for authors.
Competing Interests:We have the following
interests. This study was partly supported by a
GlaxoSmithKline and Medical Research Council
(MRC) industry partnership award. Hana Müllerová
and Kourtney Davis are employed by GSK and hold
stock and share options of GlaxoSmithKline Plc. JKQ
reports grants from MRC, grants from GSK, during
the conduct of the study; grants from MRC, grants
from BLF, personal fees from AZ, personal fees from
GSK, grants from Wellcome Trust, outside the
submitted work. JRH reports personal fees from
Pharmaceutical companies interested in COPD
including AZ, Chiesi, GSK, Novartis, Pfizer, Takeda,
outside the submitted work. Imperial College of
Science, Technology and Medicine. LS reports grants
from Wellcome Trust, during the conduct of the study;
grants from Wellcome Trust, grants from MRC, grants
from NIHR, personal fees from GSK, outside the
submitted work. There are no patents, products in
development or marketed products to declare. This
does not alter the authors’ adherence to all the PLOS
ONE policies on sharing data and materials, as
detailed online in the guide for authors.
which are entered into the GP software system and uploaded to the CPRD. Prescriptions for
drugs are recorded in the CPRD as unique product codes. The codes used to construct
AECOPD algorithms are available in the supplementary appendix (S2 File).
Strategies to ascertain AECOPD, translated into coding algorithms, were developed prior to
the beginning of the study. These were based on both previous definitions that have been used
in published papers, as well as definitions deemed to show high face validity. Face validity was
determined after discussion between respiratory, primary care physicians with experience of
UK primary care, and epidemiologists with experience in the design and analysis of studies
using large UK primary care EHR databases. We used the August 2013 CPRD build and Read
code dictionary. The fifteen algorithms are described in Table 1.
As prescription of rescue packs and acute codes used at annual reviews may be identified by
our algorithms, we developed further codelists to identify consultations during which rescue
packs were prescribed or annual reviews occurred.
Study population
COPD patients were identified in the CPRD using a previously validated strategy[11]. For this
analysis, we specifically defined COPD patients as having a record for a specific COPD Read
code, history of current or past smoking, at least two prescriptions for COPD medicines (one
Table 1. Description of the algorithms tested.
Algorithm Notes
1. Oral corticosteroid (OCS) prescription For 5–14 days
2. Antibiotic prescription For 5–14 days
3. Oral corticosteroid and antibiotic
prescription
For 5–14 days, both on the same day
4. Exacerbation Symptom deﬁnition Codes suggesting increase in two or more of:
breathlessness, cough, or sputum volume and/or
purulence
5. Exacerbation Symptom deﬁnition and oral
corticosteroid prescription
Symptom deﬁnition the same as 4. Medical codes must
have been on the same day as prescription. Duration of
prescription was not limited.
6. Exacerbation Symptom deﬁnition and
antibiotic prescription
Symptom deﬁnition the same as 4. Medical codes must
have been on the same day as prescription. Duration of
prescription was not limited.
7. Exacerbation Symptom deﬁnition and oral
corticosteroid & antibiotic prescription
Symptom deﬁnition the same as 4. Medical codes must
have been on the same day as prescription. Duration of
prescription was not limited.
8. Lower respiratory tract infection (LRTI)
code
Speciﬁcally excluding codes for pneumonia
9. LRTI code and oral corticosteroid
prescription
Medical codes must have been on the same day as
prescription. Duration of prescription was not limited.
10. LRTI code and antibiotic prescription Medical codes must have been on the same day as
prescription. Duration of prescription was not limited.
11. LRTI code and oral corticosteroid &
antibiotic prescription
Medical codes must have been on the same day as
prescription. Duration of prescription was not limited.
12. AECOPD code
13. AECOPD code and oral corticosteroid
prescription
Medical codes must have been on the same day as
prescription. Duration of prescription was not limited.
14. AECOPD code and antibiotic prescription Medical codes must have been on the same day as
prescription. Duration of prescription was not limited.
15. AECOPD code and oral corticosteroid &
antibiotic prescription
Medical codes must have been on the same day as
prescription. Duration of prescription was not limited.
doi:10.1371/journal.pone.0151357.t001
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within 4 weeks of the initial COPD Read code) and of age over 35 years at the time of the initial
COPD Read code. Inclusion was further restricted to those patients whose GP practice last col-
lection date was four months or less from the end of the study (August 2013) and were alive
and registered at the GP practice at the time of the last CPRD data collection.
Patients were followed up from January 2004, date of COPD diagnosis or date of registra-
tion with an eligible practice, whichever was later and were followed up until August 2013, date
of death, last collection date, or date of transfer out of an eligible GP practice, whichever was
earlier. The fifteen pre-specified AECOPD algorithms were used to ascertain any potential
AECOPD event which occurred during this time period.
For the validation purposes, potential AECOPD events identified via algorithms were fur-
ther selected using stratified random sampling. This procedure was designed such that it would
1) select events randomly within algorithms, 2) maximise the amount of information available
per questionnaire, and 3) select potential events from rarer algorithms preferentially over
events from algorithms which had potential events which were more common. Briefly, 1600
patients were selected such that each algorithm was represented by potential AECOPD events
in at least 100 patients. Up to 10 potential AECOPD events (up to 5 from a single algorithm)
were then randomly selected from each patient’s individual pool of AECOPD events. This pro-
cedure ensured that several dates could be enquired about for each patient; that none of the
definitions had no, or very few, potential AECOPD events in the final sample; and that the
number of dates enquired about for each patient was not so high as to make response by the
GP unlikely.
Questionnaires
We sent a short questionnaire to GPs asking them to confirm whether their patients had
AECOPD on the dates identified. GPs were allowed to respond with “Yes”, “No” or “Uncer-
tain”. We also asked about any dates in the last 12 months on which the patient had an
AECOPD, not already listed on the dates specified. Finally, we asked GPs to send copies of any
relevant material, such as extracts from patient notes or hospital discharge letters. All material
was anonymised by the CPRD before being returned to investigators. We sent two reminders
to GP practices who did not initially respond.
Outcome assessment
The reference standard for diagnosis of AECOPD was an independent review of all material
from the GP (questionnaire and other relevant material) by two respiratory physicians. Each
respiratory physician independently reviewed all available information before discussing dis-
agreements. We calculated Cohen’s Kappa to assess inter-rater agreement. Information from
CPRD on dates which the GP specified that their patient had an AECOPD, but which were not
listed on the questionnaire, were also reviewed by a respiratory physician. These events were
included in the analysis if they were judged to be an AECOPD. For potential AECOPD events
which the GP responded with “uncertain”, we obtained and reviewed anonymised medical
notes and information from the CPRD GP “free-text” field records corresponding to the appro-
priate date.
Sample size
Assuming a conservative minimum of a 50% response rate and only 100 potential events iden-
tified per algorithm (50 AECOPD events per algorithm) in the final analytical sample, we cal-
culated that the confidence intervals around example PPVs would be: 50% (95% CI, 35.5–
64.5%); 70% (95% CI, 55.4–82.1%); 90% (95% CI, 78.2–96.7%).
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Analysis
The main outcome was positive predictive value (PPV). True positives were defined as events
which were identified by the algorithm, sampled from the AECOPD pool and confirmed by
the reference standard. False positives were defined as events which were identified by the algo-
rithm, sampled from the AECOPD pool and not confirmed by the reference standard. PPV
was calculated as: True positives / (True Positives + False Positives).
To estimate the sensitivity, we used a combination of algorithm and GP identified dates of
AECOPD events in the last 12 months. True positives were defined as events (1) which were identi-
fied by the algorithm, sampled from the AECOPD pool and confirmed by the reference standard or
(2) which were listed as additional events by the GP, which were also identified by algorithm but
had not been sampled. False negatives were defined as events which were (1) listed by the GP as
additional dates, but which were not identified by the algorithm or (2) as event dates which were
identified and confirmed by the reference standard for other algorithm(s) only (i.e. confirmed events
which were not in the AECOPD pool for that algorithm, whether sampled or not). For the analysis
of sensitivity, events which occurred within two weeks of another event were considered part of the
same episode. Sensitivity was calculated as: True Positives / (True Positives + False Negatives).
We used bootstrapping to obtain cluster-robust confidence intervals for PPV and sensitiv-
ity. We excluded events which were still “uncertain” after respiratory physician review. Events
which occurred on the same day as annual reviews or rescue pack prescriptions were not
included in the main analysis.
We repeated the analysis of PPV and sensitivity restricted to those patients for whom GPs
sent additional information (patient notes and discharge summaries). In this group of patients,
respiratory physicians who were assessing questionnaires would have been able to see informa-
tion from several sources in order to reach a decision on whether they thought the patient had
an AECOPD on the dates in question. We also repeated the analysis of PPV stratified by char-
acteristics identified from the CPRD: age group, sex, smoking status, GOLD 2006 grade of air-
flow limitation[12], Medical Research Council (MRC) dyspnoea score[13], socioeconomic
status[14], WHO Body Mass Index (BMI) category, previous record of asthma diagnosis, pre-
vious records of gastro-oesophageal reflux disease (GORD) diagnosis, and previous record of
diagnosis for cardiovascular disease (either of myocardial infarction, angina or heart failure).
Finally, we assessed the PPV and sensitivity for several combinations of algorithms to iden-
tify AECOPD. Our strategy was to achieve an adequate sensitivity while maintaining a high
PPV. Initially we combined algorithms which had the highest PPV (those with PPV>80%).
We then added algorithms which had PPV>75% in order to improve sensitivity. We also cal-
culated PPV and sensitivity using all of the algorithms.
Ethics
Ethical approval was obtained from the London School of Hygiene and Tropical Medicine
(LSHTM) Observational Research Ethics Committee (approval number 6481) and the Clinical
Practice Research Datalink (CPRD) Independent Scientific Advisory Committee (ISAC)
(approval number 13_116). Patient records and questionnaires were de-identified and anon-
ymised by CPRD staff before being sent to the investigators.
Results
Patient characteristics
We selected 1600 patients for the study, of whom 215 had GP practices which had left the
CPRD and were therefore excluded from the sampling frame (Fig 1). Our final study consisted
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of questionnaires related to the remaining 1385 patients. Of these 988 (71%) were returned by
their GPs, representing 8258 potential AECOPD events. Characteristics of patients included in
the study are detailed in Table 2. Mean age in our final sample of COPD patients was 62.4
years (SD, 10.6), 49% were male, 38% had severe or very severe airflow limitation (GOLD 2006
grades 3 or 4), 53% reported moderate/severe dyspnoea (MRC score of 3 or more), and 55%
were current smokers. Restricting the sample to those dates which did not occur on annual
review dates or dates of rescue pack prescriptions reduced the sample to 7136 events in 955
patients. Characteristics of patients whose GPs responded to the questionnaire were similar to
those who did not, with the exception of socioeconomic status (Table A in S1 File). Patients
whose GPs did not respond were on average more deprived than those whose GP responded.
Details of the event flow through the study stratified by algorithm are presented in Table 3.
PPV and sensitivity
Inter-rater agreement in outcome assessment was high. The respiratory physicians reviewing
the questionnaires agreed for 92.5% of the potential AECOPD dates before discussion, and this
resulted in a Cohen’s Kappa of 0.844. All disagreements were resolved by discussion between
the two respiratory physicians and none were referred to a third physician. The PPVs and sen-
sitivity of each algorithm are presented in Table 4. The algorithms with the higher PPVs
(>80%) were those that used (1) an LRTI code along with either prescription of an antibiotic
or a steroid or antibiotic and a steroid, and (2) AECOPD code either with or without
Fig 1. Patient flow through the study.
doi:10.1371/journal.pone.0151357.g001
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prescription of antibiotics; and (3) the symptom definition with either prescription of OCS or
antibiotics. The LRTI code alone (79.6%, 76.9–82.3%) and prescription of both antibiotics and
OCS for 5–14 days (79.3%, 75.8–82.9%) had slightly lower PPVs. The symptom definition
alone, prescription for 5–14 days of antibiotics and prescription of 5–14 days of OCS had
poorer PPVs (60–73%).
Sensitivity was low (<30%) for all algorithms except for prescription of an antibiotics course
for 5–14 days (71.1%, 66.8–75.4%). More restrictive definitions had poorer sensitivity than
Table 2. Characteristics of the 988 patients included in the analysis.
Characteristic n % (N = 988)
Age group
55 212 21.5
55 to 64 359 36.3
65 to 74 301 30.5
 75 116 11.7
Sex
Male 481 48.7
Female 507 51.3
MRC breathlessness scale (N = 950)
3 449 47.3
< 3 501 52.7
BMI
< 19 39 4.0
19–25 353 35.7
25 596 60.3
Record of cardiovascular disease
No 731 74.0
Yes 257 26.0
Record of asthma
No 482 48.8
Yes 506 51.2
Record of GORD
No 729 73.8
Yes 259 26.2
GOLD 2006 grade (N = 592)
1 76 12.8
2 285 48.1
3 185 31.3
4 46 7.8
Smoking status
Ex-smoker 447 45.2
Current smoker 541 54.8
Index of multiple deprivation quintile (N = 985)
1 (least deprived) 152 15.4
2 213 21.6
3 188 19.1
4 216 21.9
5 (most deprived) 216 21.9
doi:10.1371/journal.pone.0151357.t002
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those without any restriction. Sensitivity was particularly low for all of the algorithms which
used respiratory symptoms.
Restricting the analysis to those patients for whom GPs sent supporting information
resulted in slight increases in PPV for some algorithms (Table 5). This restriction also reduced
the sensitivity for the use of OCS for 5–14 days to 22.7% (95% CI, 16.1–29.2%) from 30.2%
(95% CI, 25.8–34.6%); the use of antibiotics for 5–14 days to 63.4% (95% CI, 55.4–71.4%) from
71.1% (95% CI, 66.8–75.4%); and the use of both antibiotics and OCS for 5–14 days to 18.6%
(95% CI, 12.4–24.7%) from 24.5% (95% CI, 20.4–28.6%).
The analysis of PPV and sensitivity analyses were repeated for all event date including these
dates occurring on annual COPD review and those with prescription for suspected rescue
packs of OCS (Table B in S1 File). The PPVs stratified by patient demographic and disease
severity characteristics are presented in the supplementary material (Tables C-L in S1 File).
Briefly, PPVs for the OCS course for 5–14 days appeared to differ by some of the characteris-
tics. PPV for the OCS course for 5–14 days was higher for patients with no or mild dyspnoea,
without CVD co-morbidity, and for women.
Table 3. Flow of events through the study.
Algorithm N events
identiﬁed in the
CPRD
N events
sampled
N events from
returned
questionnaires
N events adjudicated
for uncertain
response
N events uncertain after respiratory
physician review (% of those
returned questionnaires)
All 261981 11697 8253 914 227 (2.8)
1.OCS prescription for
5–14 days
33898 1956 1285 120 32 (2.5)
2.Antibiotic prescription
for 5–14 days
225761 9622 6283 809 208 (3.3)
3.OCS and antibiotic
prescription for 5–14
days
22990 1374 919 72 22 (2.4)
4. Symptom deﬁnition 1745 462 341 11 2 (0.6)
5. Symptom deﬁnition
and OCS prescription
553 232 156 6 1 (0.6)
6. Symptom deﬁnition
and antibiotic
prescription
165 132 108 5 0 (0)
7. Symptom deﬁnition
and OCS & antibiotic
prescription
142 112 90 3 0 (0)
8. LRTI code 60099 2753 1809 214 36 (2.0)
9. LRTI code and OCS
prescription
53460 2488 1617 200 34 (2.1)
10. LRTI code and
antibiotic prescription
9354 600 411 25 2 (0.5)
11. LRTI code and OCS
& antibiotic prescription
8770 569 388 25 2 (0.5)
12. AECOPD code 20905 1371 966 21 0 (0)
13. AECOPD code and
OCS prescription
15020 992 698 14 0 (0)
14. AECOPD code and
antibiotic prescription
8571 674 466 11 0 (0)
15. AECOPD code and
OCS & antibiotic
prescription
7440 601 418 10 0 (0)
doi:10.1371/journal.pone.0151357.t003
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The PPV and sensitivity for the composite strategies are presented in Table 6. Combining
algorithms with PPV> 80% (5, 6, 8 or 12) resulted in a PPV of 88.1% (95% CI, 85.3–90.8) and
a sensitivity of 51.6 (95% CI, 44.1–59.0). Using algorithms with a PPV>75% (3, 5, 6, 8 or 12)
resulted a in very high PPV of 85.5% (95%CI, 82.7–88.3%) with a sensitivity of 62.9% (95%CI,
Table 4. PPV and sensitivity for the algorithms.
Algorithm N events
identiﬁed in the
CPRD
N events conﬁrmed
by reference
standard
PPV
(95% CI)
N events identiﬁed
in the CPRD in last
year
N extra events identiﬁed
by other algorithms or
GPs in last year
Sensitivity
(95% CI)
1.OCS prescription 1152 841 73.0
(69.5–
76.5)
164 379 30.2(25.8–
34.6)
2.Antibiotic prescription 5840 3559 60.9
(59.0–
62.9)
386 157 71.1 (66.8–
75.4)
3.OCS and antibiotic
prescription
823 653 79.3
(75.8–
82.9)
133 410 24.5 (20.4–
28.6)
4. Symptom deﬁnition 142 92 64.8
(56.2–
73.3)
14 529 2.6 (1.1–4.0)
5. Symptom deﬁnition
and OCS prescription
88 79 89.8
(82.9–
96.7)
12 531 2.2 (0.9–3.6)
6. Symptom deﬁnition
and antibiotic
prescription
57 53 93.0
(85.6–
100.0)
10 533 1.8 (0.6–3.1)
7. Symptom deﬁnition
and OCS & antibiotic
prescription
48 47 97.9
(94.5–
100.0)
9 534 1.7 (0.5–2.9)
8. LRTI code 1745 1389 79.6
(76.9–
82.3)
125 418 23.0 (19.2–
26.8)
9. LRTI code and OCS
prescription
1558 1268 81.4
(78.7–
84.1)
108 435 19.9 (16.3–
23.5)
10. LRTI code and
antibiotic prescription
393 347 88.3
(84.4–
92.2)
65 478 12.0 (9.3–
14.7)
11. LRTI code and OCS
& antibiotic prescription
371 327 88.1
(84.1–
92.1)
62 481 11.4 (8.8–
14.0)
12. AECOPD code 885 850 96.0
(94.5–
97.6)
136 407 25.1 (20.9–
29.2)
13. AECOPD code and
OCS prescription
638 618 96.9
(95.4–
98.3)
99 444 18.2 (14.6–
21.8)
14. AECOPD code and
antibiotic prescription
423 408 96.5
(94.5–
98.4)
95 448 17.5 (13.8–
21.2)
15. AECOPD code and
OCS & antibiotic
prescription
377 365 96.8
(95.0–
98.6)
87 456 16.0 (12.6–
19.5)
Antibiotics = selected antibiotics with clinical application in management of AECOPD
OCS = oral corticosteroids speciﬁc to AECOPD management
doi:10.1371/journal.pone.0151357.t004
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Table 5. PPV and sensitivity of the algorithms to identify AECOPD including only patients for whom additional information was available from
their GP questionnaire.
Algorithm (inclusive
deﬁnitions)
N events
identiﬁed in the
CPRD
N events conﬁrmed
by reference
standard
PPV
(95% CI)
N events identiﬁed
in the CPRD in last
year
N extra events
identiﬁed by GPs in
last year
Sensitivity
(95% CI)
1.OCS prescription 367 265 72.2
(66.5–
77.9)
44 150 22.7 (16.1–
29.2)
2.Antibiotic prescription 2245 1376 61.3
(58.3–
64.3)
123 71 63.4 (55.4–
71.4)
3.OCS and antibiotic
prescription
251 200 79.7
(73.5–
85.8)
36 158 18.6 (12.4–
24.7)
4. Symptoms deﬁnition 83 53 63.9
(52.7–
75.0)
4 190 2.1 (0.1–4.0)
5. Symptoms deﬁnition and
OCSPrescription
50 47 94.0
(88.0–
100.0)
4 190 2.1 (0.1–4.0)
6. Symptoms deﬁnition and
antibiotic prescription
36 34 94.4
(86.8–
100.0)
3 191 1.6 (0.1–3.2)
7. Symptoms deﬁnition and
OCS & antibiotic
prescription
31 31 100.0
(88.8–
100.0)
3 191 1.6 (0.1–3.2)
8. LRTI code 693 574 82.8
(78.8–
86.9)
48 146 24.7 (18.8–
30.7)
9. LRTI code and OCS
prescription
621 525 84.5
(80.6–
88.5)
40 154 20.6 (15.2–
26.0)
10. LRTI code and antibiotic
prescription
142 132 93.0
(88.3–
97.6)
24 170 12.4 (7.8–
16.9)
11. LRTI code and OCS &
antibiotic prescription
129 119 92.2
(87.1–
97.4)
21 173 10.8 (6.7–
15.0)
12. AECOPD code 350 344 98.3
(96.9–
99.6)
52 142 26.8 (19.7–
33.9)
13. AECOPD code and OCS
prescription
236 234 99.2
(98.1–
100.0)
36 158 18.6 (12.4–
24.7)
14. AECOPD code and
antibiotic prescription
155 152 98.1
(96.0–
100.0)
33 161 17.0 (10.8–
23.2)
15. AECOPD code and OCS
& antibiotic prescription
140 138 98.6
(96.8–
100.0)
30 164 15.5 (9.7–
21.2)
Antibiotics = selected antibiotics with clinical application in management of AECOPD
OCS = oral corticosteroids speciﬁc to AECOPD management
doi:10.1371/journal.pone.0151357.t005
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55.4–70.4%). Use of all pre-defined algorithms to identify AECOPD reduced the PPV to 63.8%
(95%CI, 61.0–66.6%), but achieved a sensitivity of 88.1% (95%CI, 82.9–93.4%).
Discussion
This is the first study to describe the recording of AECOPD by general practitioners in UK
EHRs. Although the definitions used in future studies may depend on the individual needs and
potential objectives, particularly with respect to the need for maximising either PPV or sensi-
tivity, our recommendation for identifying AECOPD events in EHR is to use a composite of
several of the definitions with higher PPV. To maximise sensitivity over PPV for identifying
AECOPD in UK EHR, investigators would need to use prescription of antibiotics, as the PPV
was low for this algorithm, this strategy is likely to misclassify many other infections as
AECOPD. One recommended approach would be to use the following strategy that resulted in
PPV of 86% and sensitivity of 63%: a combination of: (1) a medical diagnosis of LRTI or
AECOPD, or (2) a prescription of COPD-specific antibiotic combined with OCS for 5–14
days, or (3) a record of two or more respiratory symptoms of AECOPD along with a prescrip-
tion of COPD-specific antibiotics and/or OCS on the same day. These combined strategies
should be used only after removing any AECOPD events occurring on the same date as codes
suggestive of a visit for annual COPD review or provision of rescue packs for COPD-specific
antibiotics or OCS. We do not recommend using definitions based on respiratory symptoms
without COPD-specific antibiotics or OCS, or COPD-specific antibiotics or OCS without med-
ical diagnosis of LRTI, AECOPD or respiratory symptoms due to mediocre PPVs. This has
important implications as previous studies of AECOPD outcomes have used prescription of
either antibiotics and or oral steroids to define AECOPD, and our findings suggest that this
strategy may lead to a high level of misclassification of AECOPD events. Compared to previous
studies, which have attempted to identify AECOPD in EHRs, we used a very specific list of
antibiotics and OCS pertaining to management of AECOPD.
Having a validated definition of a COPD outcome, representing a substantial source of bur-
den to patients and health-care providers, such as AECOPD is important. It provides a robust
method for deriving statistics on AECOPD which can inform health-care service planning and
evaluation of programs over time. In addition, as well as being a resource for “real life” observa-
tional studies, electronic healthcare records have the potential to be used in pragmatic clinical
trials. This requires standardised and accurate definitions of exacerbations, and our research
provides that.
Our findings illustrate that there are multiple strategies adopted by health care workers
when recording AECOPD events in the UK EHR. Only about one half of the AECOPD events
were recorded using a medical diagnosis code either for LRTI, AECOPD or respiratory
Table 6. PPV and sensitivity of composite strategies to identify AECOPD including only patients for
whom additional information was available from their GP questionnaire.
Strategy PPV (95%
CI)
Sensitivity (95%
CI)
Algorithms with PPV > 80% Algorithms 5, 6, 8 or 12: Symptom
deﬁnition with prescription of antibiotic or OCS; or LRTI; or AECOPD
code
88.1 (85.3–
90.8)
51.6 (44.1–59.0)
Algorithms with PPV > 75% Algorithms 3, 5, 6, 8 or 12: Prescription of
antibiotics and OCS for 5–14 days; or Symptom deﬁnition with
prescription of antibiotic or OCS; or LRTI code; or AECOPD code
85.5 (82.7–
88.3)
62.9 (55.4–70.4)
All algorithms 63.8 (61.0–
66.6)
88.1 (82.9–93.4)
doi:10.1371/journal.pone.0151357.t006
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symptoms, whilst the remaining events were recorded only as prescriptions of COPD-specific
antibiotics and/or OCS. Even using all pre-defined algorithms, about 12% of AECOPD events
failed to be captured (false negatives). We explored medical codes at these dates and did not
find any leads allowing derivation of further algorithms. The most frequent events recorded on
the AECOPD dates not captured by any algorithm included: “reviewed patient”, “home visit”
or single symptoms. This heterogeneity makes ascertainment of AECOPD events challenging.
We recommend that AECOPD events are recorded consistently by care providers, preferably
using medical diagnosis codes stating AECOPD, and that these codes are recorded only at the
time of acute events and not to record a historical number of prior episodes. This should be
achieved through better education of prescribers, but also by improving health-care informa-
tion systems to enable health care workers an easy and consistent way to record severity of
AECOPD into EHRs, including patient reported AECOPD as milder events and retrieving hos-
pital discharges for AECOPD. Moreover, AECOPD events which are treated by community
COPD teams should be reported to GPs via linked health-care information systems to provide
an integrated record of critical events. Ideally, GPs should be able to access AECOPD history of
their patients with a “one-click” menu given its prognostic value, allowing for individually tar-
geted treatment strategies for COPD patients at high risk of future events. One of the strengths
of this study is the robust reference standard used to identify episodes of AECOPD though
respiratory physicians independent adjudication of supplementary information from GPs as
well as the anonymized “free-text” notes section from the CPRD.
Although we obtained information on AECOPD from GPs, there were still limitations to
the available data. To maximize the rigor of the study, we used respiratory physician review of
all available information as the reference standard, and we have presented a sensitivity analysis
of only those events for which additional information was available. Although we had a reason-
able response rate, GPs whose patients were more deprived were less likely to respond to our
questionnaire and the extent to which the coding practices differ in association with patient
deprivation level could not be determined. In addition, because we needed patients to be alive
at the time of the study, our results may not be generalisable to those with the most severe
COPD. Another limitation is that by using EHR to identify AECOPD, we will miss events
which are self-managed by COPD patients, and therefore this study does not capture the full
range of severity. Our results should therefore be interpreted as the accuracy of AECOPD
events recorded by primary care clinicians. Our stratified analysis of PPV presented in the sup-
plementary material showed that the algorithms based on symptom definitions and prescrip-
tion of OCS alone for 5–14 days had different PPV depending on patient characteristics. These
differences could potentially cause bias, however we do not recommend that prescription of
OCS for 5–14 days alone is used to identify AECOPD, and the symptom-based definitions only
contribute to a small number of the AECOPD events. In addition, the PPVs for definitions
included in our recommended strategy (based on LRTI codes, AECOPD codes and prescrip-
tion of both antibiotics and OCS) did not vary significantly depending on patient characteris-
tics. Our recommended strategy for identifying AECOPD achieved a high PPV, however the
sensitivity was lower, suggesting that although this strategy is valid it will tend to underestimate
the number of events. One option for investigators wishing to assess the burden of AECOPD is
to conduct an analysis using both a strategy with high PPV and one with high sensitivity in
order to estimate a minimum and maximum number of events per patient. Our study was con-
ducted in the UK, and this may limit generalisability of the results to EHR databases which col-
lect data from other countries. Although we used definitions of AECOPD used in previous
studies to develop our algorithms, it may be difficult to relate our findings to the validity of
some previously used definitions. This is for two reasons, firstly, in order to achieve high valid-
ity, we used a narrow list of antibiotics in our algorithms. This is likely to have increased the
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PPV of our algorithms, and studies which used a broader list of antibiotics may have lower
PPV for AECOPD identification. Secondly, poor reporting of previously used definitions of
AECOPD mean that it is difficult to relate these to our current findings. One further limitation
of the analysis presented here is that these results do not include hospital events, however this
is the focus of a current study. This limitation should not affect the PPV, however this does
mean that our estimates of sensitivity relate to events which are treated/recorded in primary
care only and not the total number of AECOPD events.
We have validated strategies to identify AECOPD within electronic healthcare records,
however our strategies may underestimate the total number of true AECOPD events. Our
results should be used for future research studies and by public health bodies when identifying
AECOPD in the UK. We found that some previously used definitions have low PPV. Our
results also highlight the lack of standardisation of the recording of AECOPD in EHRs, and
efforts should be made to standardise the recording of AECOPD within EHRs.
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